Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Gross Profit (2020 - 2025)

Historic Gross Profit for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $63.4 million.

  • Xeris Biopharma Holdings' Gross Profit rose 5583.04% to $63.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.0 million, marking a year-over-year increase of 4762.62%. This contributed to the annual value of $166.2 million for FY2024, which is 2289.44% up from last year.
  • Xeris Biopharma Holdings' Gross Profit amounted to $63.4 million in Q3 2025, which was up 5583.04% from $59.6 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Gross Profit high stood at $63.4 million for Q3 2025, and its period low was $5.5 million during Q2 2021.
  • In the last 5 years, Xeris Biopharma Holdings' Gross Profit had a median value of $30.5 million in 2023 and averaged $31.6 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Gross Profit soared by 32107.94% in 2021 and then surged by 138.59% in 2024.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Gross Profit stood at $16.5 million in 2021, then surged by 62.35% to $26.9 million in 2022, then surged by 37.12% to $36.8 million in 2023, then surged by 37.48% to $50.6 million in 2024, then grew by 25.21% to $63.4 million in 2025.
  • Its last three reported values are $63.4 million in Q3 2025, $59.6 million for Q2 2025, and $51.4 million during Q1 2025.